首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   310257篇
  免费   28755篇
  国内免费   21714篇
耳鼻咽喉   3082篇
儿科学   3609篇
妇产科学   4915篇
基础医学   37253篇
口腔科学   5473篇
临床医学   40075篇
内科学   45645篇
皮肤病学   2975篇
神经病学   17824篇
特种医学   11964篇
外国民族医学   216篇
外科学   32801篇
综合类   49733篇
一般理论   20篇
预防医学   18994篇
眼科学   9491篇
药学   32371篇
  235篇
中国医学   17578篇
肿瘤学   26472篇
  2024年   193篇
  2023年   4514篇
  2022年   6937篇
  2021年   12624篇
  2020年   12332篇
  2019年   14228篇
  2018年   9005篇
  2017年   9675篇
  2016年   7950篇
  2015年   13382篇
  2014年   17452篇
  2013年   14912篇
  2012年   22189篇
  2011年   25103篇
  2010年   15870篇
  2009年   12236篇
  2008年   17000篇
  2007年   17009篇
  2006年   17048篇
  2005年   16764篇
  2004年   10652篇
  2003年   9754篇
  2002年   8416篇
  2001年   7438篇
  2000年   8259篇
  1999年   8952篇
  1998年   5329篇
  1997年   5391篇
  1996年   4228篇
  1995年   3914篇
  1994年   3216篇
  1993年   2096篇
  1992年   2823篇
  1991年   2413篇
  1990年   2106篇
  1989年   1852篇
  1988年   1557篇
  1987年   1296篇
  1986年   1079篇
  1985年   906篇
  1984年   516篇
  1983年   363篇
  1982年   231篇
  1981年   224篇
  1980年   184篇
  1979年   221篇
  1978年   82篇
  1977年   89篇
  1974年   101篇
  1973年   83篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
9.
In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise system of diagnosis and treatment for ccRCC. Expression profiles of 1079 tumor samples of ccRCC patients (including 311 patients treated with everolimus or nivolumab) were downloaded from public databases. Proteomic profiles of 232 ccRCC samples were obtained from Fudan University Shanghai Cancer Center (FUSCC). Biological changes, tumor microenvironment and prognostic differences were explored between samples with various glycolysis characteristics. There were significant differences in CD8+ effector T cells, epithelial-to-mesenchymal transition and pan-fibroblast TGFb between the Low and High glyScore groups. The tumor mutation burden of the Low glyScore group was lower than that of the High glyScore group. And higher glyScore was significantly associated with worse overall survival (OS) in 768 ccRCC patients (P < .0001). External validation in FUSCC cohort also indicated that glyScore was of strong ability for predicting OS (P < .05). GlyScore may serve as a biomarker for predicting everolimus response in ccRCC patients due to its significant associations with progression-free survival (PFS). And glyScore may also predict overall survival in patients treated with nivolumab. We calculated the glyScore in ccRCC and the defined glyScore was of strong ability for predicting OS. In addition, glyScore may also serve as a biomarker for predicting PFS in patients treated with everolimus and could predict OS in patients treated with nivolumab.  相似文献   
10.
The purpose of this study was to provide an evidence base for colorectal cancer research activity that might influence policy, mainly at the national level. Improvements in healthcare delivery have lengthened life expectancy, but within a situation of increased cancer incidence. The disease burden of CRC has risen significantly, particularly in Africa, Asia and Latin America. Research is key to its control and reduction, but few studies have delineated the volume and funding of global research on CRC. We identified research papers in the Web of Science (WoS) from 2007 to 2021, and determined the contributions of the leading countries, the research domains studied, and their sources of funding. We identified 62 716 papers, representing 5.7% of all cancer papers. This percentage was somewhat disproportionate to the disease burden (7.7% in 2015), especially in Eastern Europe. International collaboration increased over the time period in almost all countries except in China. Genetics, surgery and prognosis were the leading research domains. However, research on palliative care and quality-of-life in CRC was lacking. In Western Europe, the main funding source was the charity sector, particularly in the UK, but in most other countries government played the leading role, especially in China and the USA. There was little support from industry. Several Asian countries provided minimal contestable funding, which may have reduced the impact of their CRC research. Certain countries must perform more CRC research overall, especially in domains such as screening, palliative care and quality-of-life. The private-non-profit sector should be an alternative source of support.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号